Showing 7211-7220 of 8649 results for "".
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Euclid Vision Issues Statement on the Passing of Co-Founder George Gladyhttps://modernod.com/news/euclid-vision-issues-statement-on-the-passing-of-co-founder-george-glady/2481771/Euclid Vision issued a statement memorializing George Glady, one of the company's founders who has passed away. Mr. Glady was a pioneer in Ortho-K, which has been an innovation used by millions of patients around the world to slow the progression of myopia. The state
- Oculis’ OCS-01 Eye Drops Studied in LEOPARD Trial to Treat Cystoid Macular Edemahttps://modernod.com/news/oculis-ocs-01-eye-drops-studied-in-leopard-trial-to-treat-cystoid-macular-edema/2481763/Oculis announced that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ high-concentration preservative-free topical Optireach formulation of dexamethasone, for the treatment of cystoid macular edema (CME).<
- HelpMeSee and USAID Partner to Train New Cataract Specialists to Provide Surgical Care for India's Cataract Blindhttps://modernod.com/news/helpmesee-and-usaid-partner-to-train-new-cataract-specialists-to-provide-surgical-care-for-indias-cataract-blind/2481752/HelpMeSee announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has p
- Glauconix Changes Name to Humonixhttps://modernod.com/news/glauconix-changes-name-to-humonix/2481751/Glauconix Biosciences has changed its name to Humonix Biosciences as the company has expanded beyond glaucoma to technology can support various cell types. "What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular
- Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United Stateshttps://modernod.com/news/versea-ophthalmics-will-distribute-celularitys-biovance-and-biovance-3l-ocular-products-in-the-united-states/2481750/Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Study Identifies How Diabetes Slows Healing in the Eyehttps://modernod.com/news/study-identifies-how-diabetes-slows-healing-in-the-eye/2481742/Investigators from Cedars-Sinai have provided new understanding of how diabetes delays wound healing in the eye, identifying for the first time two related disease-associated changes to the cornea, according to a company news release.
- BVI Expands IOL Capacity with New Facility in Belgiumhttps://modernod.com/news/bvi-expands-iol-capacity-with-new-facility-in-belgium/2481738/BVI has announced the opening of a new facility in Liège, Belgium that increases the company's IOL business capacity. BVI says the facility will unlock new growth opportunities while reinforcing the company’s environmental, social, and governance (ESG) leaders
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th